Table 1.

Arterial pressure, body weight, heart weight, heart rate, LV diameter and fractional shortening measured by echocardiography, plasma renin activity and cardiac ACE activity

	RS (n=12)	HS (n=12)	HS+Irbesartan (n=12)	HS+Ramipril (n=12)
Systolic blood pressure, mmHg
Baseline	125±3	123±4	124±2	124±2
8 weeks	127±2	126±3	125±2	122±1
Body weight, g
Baseline	33.9±0.8	34.8±0.6	33.4±0.6	33.2±0.6
8 weeks	42.6±1.3‡	42.5±1.0‡	42.1±1.0‡	41.9±0.8‡
Food intake, g/24h	6.4±0.2	6.7±0.3	6.3±0.2	6.2±0.3
Water intake, ml/24h	6.0±0.8	10.9±0.5 *	11.2±0.4 *	12.5±1.2 *
Heart weight, mg	188±6	218±5 *	178±3†	184±5†
Heart/body weight ratio	4.3±0.1	5.3±0.1 *	4.2±0.1†	4.4±0.2†
LV weight #, mg	135±4	158±5 *	128±2†	132±6†
LV/body weight ratio #	2.9±0.1	3.6±0.2 *	3.1±0.1†	3.1±0.2†
Heart rate, beats/min
Baseline	284±16	273±15	294±12	291±12
8 weeks	257±13	270±13	267±13	270±10
LVEDD, mm
Baseline	4.4±0.1	4.4±0.1	4.4±0.1	4.4±0.1
8 weeks	4.8±0.1‡	4.8±0.1‡	4.7±0.1‡	4.7±0.1‡
Fractional shortening, %
Baseline	34±1	33±1	30±3	33±2
8 weeks	35±6	34±2	34±1	32±2
Cardiac ACE activity #, nmol/mg protein	3.4±0.3	5.6±0.3*	5.5±0.2*	3.9±0.2†

RS: regular salt diet (0.6% NaCL); HS: high salt diet (4% NaCl); HS+Irbesartan: HS diet plus irbesartan (50 mg/kg/day); HS+Ramipril: HS diet plus ramipril (1 mg/kg/day); LV: left ventricle; LVEDD: LV end-diastolic diameter.

^#LV weight and LV/Body weight ratio were measured in 6 mice of each group after 8 weeks of salt diets and treatments.

^#cardiac ACE activity were measured in 5 mice in each group. There was no difference in systolic blood pressure between groups at baseline and after 8 weeks of salt diet and treatment.

^*p<0.05 versus RS mice,

^†p<0.05 versus HS and

^‡p<0.05 versus corresponding baseline.